Study details
Enrolling now
A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)
Turn Therapeutics
NCT IDNCT07355075ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 12 months
Ages
18–70
Locations
1 site in TX
What this study is about
This trial is testing a new treatment, GX-03, for moderate to severe eczema. Participants will apply GX-03 or a vehicle control on their skin for 8 weeks and doctors will measure how well the treatment works using several methods. The study will also monitor any side effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take GX-03
- 2.Vehicle
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Change in NRS Max Itch
Body systems
Dermatology